ALX ONCOLOGY HOLDINGS

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Scott Garland to its Board of Directors

29 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

02 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

31 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 Oct 2022 07:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

21 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

01 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

15 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

11 Aug 2022 06:00:02 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia

29 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Evorpacept Clinical Program Updates

03 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference

01 Jun 2022 06:00:02 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

09 May 2022 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

12 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

02 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

27 Jan 2022 16:51:25 By Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

10 Jan 2022 05:00:00 By Nasdaq GlobeNewswire